<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
RPRX
Royalty Pharma
$
()


  • Ionis Pharmaceuticals price target raised by $7 at Oppenheimer, here's why

    3/6/2024 - 08:17am
  • Royalty Pharma reports Q4 revenue $596M, consensus $691.65M

    2/15/2024 - 07:34am
  • Royalty Pharma increases quarterly dividend 5% to 21c per share

    1/19/2024 - 08:16am
  • Royalty Pharma sees 2023 Porfolio Receipts of $3.05B

    1/8/2024 - 07:21am
  • Royalty Pharma director sells $13.2M in common stock as part of option exercise

    1/4/2024 - 17:26pm
  • Royalty Pharma price target lowered by $11 at Morgan Stanley, here's why

    12/12/2023 - 07:36am
  • Royalty Pharma to fund up to $125M for LAI Program in collaboration with Teva

    11/13/2023 - 08:16am
  • Royalty Pharma Q3 revenue $536M, consensus $614.36M

    11/8/2023 - 07:13am
  • What You Missed On Wall Street On Thursday

    10/19/2023 - 16:26pm
  • What You Missed On Wall Street This Morning

    10/19/2023 - 12:10pm
  • PTC Therapeutics signs royalty agreement with Royalty Pharma for Evrysdi

    10/19/2023 - 08:06am
  • Royalty Pharma appoints Schneider as Chief Technology Officer

    9/21/2023 - 08:26am
  • Ascendis Pharma price target raised to $113 from $107 at BofA

    9/7/2023 - 06:26am
  • Ascendis Pharma and Royalty Pharma enter into $150M royalty funding pact

    9/5/2023 - 16:05pm
  • Royalty Pharma, Ferring Pharma sign $500M royalty agreement for Adstiladrin

    8/24/2023 - 06:34am
dynamic_feed Breaking News